Rapid non-destructive volumetric tumor yield assessment in fresh lung core needle biopsies using polarization sensitive optical coherence tomography.
Journal
Biomedical optics express
ISSN: 2156-7085
Titre abrégé: Biomed Opt Express
Pays: United States
ID NLM: 101540630
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
received:
04
06
2021
revised:
30
07
2021
accepted:
01
08
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Adequate tumor yield in core-needle biopsy (CNB) specimens is essential in lung cancer for accurate histological diagnosis, molecular testing for therapeutic decision-making, and tumor biobanking for research. Insufficient tumor sampling in CNB is common, primarily due to inadvertent sampling of tumor-associated fibrosis or atelectatic lung, leading to repeat procedures and delayed diagnosis. Currently, there is no method for rapid, non-destructive intraprocedural assessment of CNBs. Polarization-sensitive optical coherence tomography (PS-OCT) is a high-resolution, volumetric imaging technique that has the potential to meet this clinical need. PS-OCT detects endogenous tissue properties, including birefringence from collagen, and degree of polarization uniformity (DOPU) indicative of tissue depolarization. Here, PS-OCT birefringence and DOPU measurements were used to quantify the amount of tumor, fibrosis, and normal lung parenchyma in 42 fresh, intact lung CNB specimens. PS-OCT results were compared to and validated against matched histology in a blinded assessment. Linear regression analysis showed strong correlations between PS-OCT and matched histology for quantification of tumors, fibrosis, and normal lung parenchyma in CNBs. PS-OCT distinguished CNBs with low tumor content from those with higher tumor content with high sensitivity and specificity. This study demonstrates the potential of PS-OCT as a method for rapid, non-destructive, label-free intra-procedural tumor yield assessment.
Identifiants
pubmed: 34692203
doi: 10.1364/BOE.433346
pii: 433346
pmc: PMC8515979
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5597-5613Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL132120
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL152075
Pays : United States
Informations de copyright
© 2021 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.
Déclaration de conflit d'intérêts
LPH: Boehringer Ingelheim, Pliant Therapeutics, LX Medical, and Biogen Idec. MJS: NinePoint Medical, LX Medical.
Références
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Gastrointest Endosc. 2008 Oct;68(4):745-53
pubmed: 18926183
Biomed Opt Express. 2017 Sep 26;8(10):4729-4741
pubmed: 29082098
J Vis Exp. 2013 Jan 22;(71):
pubmed: 23381470
J Oncol Pract. 2018 Oct 4;:JOP1800092
pubmed: 30285529
Chest. 2012 Aug;142(2):385-393
pubmed: 21980059
Biomed Opt Express. 2019 Jul 24;10(8):4190-4206
pubmed: 31453004
Science. 1991 Nov 22;254(5035):1178-81
pubmed: 1957169
Cancer Cytopathol. 2013 Jan;121(1):4-8
pubmed: 22760969
J Biomed Opt. 2002 Jul;7(3):359-71
pubmed: 12175285
Arch Ophthalmol. 1995 Mar;113(3):325-32
pubmed: 7887846
Ann Thorac Surg. 2007 Dec;84(6):1825-9
pubmed: 18036892
Eur Respir J. 2014 Oct;44(4):1011-22
pubmed: 25102961
Chest. 2007 Sep;132(3 Suppl):131S-148S
pubmed: 17873165
Opt Lett. 2014 Dec 15;39(24):6783-6
pubmed: 25502996
JAMA. 2012 Jun 13;307(22):2418-29
pubmed: 22610500
JACC Cardiovasc Imaging. 2008 Nov;1(6):752-61
pubmed: 19356512
Cancer Res. 2020 Apr 15;80(8):1773-1783
pubmed: 32295783
Clin Cancer Res. 2019 Sep 1;25(17):5242-5249
pubmed: 31175092
Am J Respir Crit Care Med. 2013 Jan 15;187(2):125-9
pubmed: 23322794
Biomed Opt Express. 2019 May 30;10(6):3070-3091
pubmed: 31259075
Opt Express. 2013 Jul 15;21(14):16353-69
pubmed: 23938487
Pathology. 2017 Oct;49(6):611-617
pubmed: 28811084
Sci Rep. 2016 Jul 01;6:28771
pubmed: 27364229
Sci Transl Med. 2016 Oct 5;8(359):359ra131
pubmed: 27708064
Nat Med. 2006 Dec;12(12):1429-33
pubmed: 17115049
Cancer Res. 2015 Oct 1;75(19):4032-41
pubmed: 26282168
Biomed Opt Express. 2018 Feb 09;9(3):1082-1096
pubmed: 29541505
Opt Lett. 2020 May 15;45(10):2748-2751
pubmed: 32412457
Histopathology. 2012 Mar;60(4):531-46
pubmed: 21916947
Oncologist. 2019 Dec;24(12):1570-1576
pubmed: 31152082
J Thorac Oncol. 2006 May;1(4):324-7
pubmed: 17409878
Biomed Opt Express. 2017 Feb 24;8(3):1838-1873
pubmed: 28663869
J Thorac Oncol. 2010 Apr;5(4):448-52
pubmed: 20125040
Biomed Opt Express. 2018 Nov 28;9(12):6519-6528
pubmed: 31065446
Nat Biomed Eng. 2017 Jul;1(7):
pubmed: 29750130
JCO Precis Oncol. 2018;2018:
pubmed: 30370396